NCT00560508 - A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

November 30, 2009

Conditions

Parkinson Disease

Interventions

DRUG

Pramipexole Immediate Release

titrated as individually needed (0.25 mg - 4.5 mg daily)

DRUG

Pramipexole Extended Release

titration as individually needed (0.375 mg -4.5 mg daily)

Trial Locations (19)

248.610.019 Boehringer Ingelheim Investigational Site, Akashi, Hyogo

248.610.020 Boehringer Ingelheim Investigational Site, Akita, Akita

248.610.006 Boehringer Ingelheim Investigational Site, Aomori, Aomori

248.610.017 Boehringer Ingelheim Investigational Site, Asahikawa, Hokkaido

248.610.018 Boehringer Ingelheim Investigational Site, Asahikawa, Hokkaido

248.610.001 Boehringer Ingelheim Investigational Site, Bunkyo-ku, Tokyo

248.610.014 Boehringer Ingelheim Investigational Site, Fuchu, Tokyo

248.610.011 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

248.610.015 Boehringer Ingelheim Investigational Site, Iwamizawa,Hokkaido

248.610.003 Boehringer Ingelheim Investigational Site, Kodaira, Tokyo

248.610.008 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

248.610.021 Boehringer Ingelheim Investigational Site, Kyoto, Kyoto

248.610.010 Boehringer Ingelheim Investigational Site, Morioka, Iwate

248.610.005 Boehringer Ingelheim Investigational Site, Okayama, Okayama

248.610.012 Boehringer Ingelheim Investigational Site, Osaka, Osaka

248.610.004 Boehringer Ingelheim Investigational Site, Sagamihara, Kanagawa

248.610.009 Boehringer Ingelheim Investigational Site, Shimogyo-ku, Kyoto, Kyoto

248.610.007 Boehringer Ingelheim Investigational Site, Shiroishi, Miyagi

248.610.002 Boehringer Ingelheim Investigational Site, Takamatsu, Kagawa